The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19

Maksim V. Baranov; Frans Bianchi; Geert van den Bogaart

doi:10.3390/cells10010030

The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19

Maksim V. Baranov, Frans Bianchi, Geert van den Bogaart^*

^*Corresponding author voor dit werk

Molecular Immunology

Onderzoeksoutput: Article › Academic › peer review

29 Citaten (Scopus)

151 Downloads (Pure)

Samenvatting

The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidence from both in vitro studies and the clinic that apilimod blocks antiviral immune responses. We therefore warn that the immunosuppression observed in many COVID-19 patients might be aggravated by apilimod.

Originele taal-2	English
Artikelnummer	30
Aantal pagina's	5
Tijdschrift	Cells
Volume	10
Nummer van het tijdschrift	1
DOI's	https://doi.org/10.3390/cells10010030
Status	Published - jan.-2021

Toegang tot document

10.3390/cells10010030Licentie: CC BY

The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19 Final publisher's version, 765 KBLicentie: CC BY

Handle.net

Permanente koppeling

Citeer dit

@article{76ea4d5ab070477989222709dba74ea2,

title = "The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19",

abstract = "The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidence from both in vitro studies and the clinic that apilimod blocks antiviral immune responses. We therefore warn that the immunosuppression observed in many COVID-19 patients might be aggravated by apilimod.",

keywords = "SARS-CoV-2, COVID-19, apilimod, LAM-002A, STA-5326, PIKfyve",

author = "Baranov, \{Maksim V.\} and Frans Bianchi and \{van den Bogaart\}, Geert",

year = "2021",

month = jan,

doi = "10.3390/cells10010030",

language = "English",

volume = "10",

journal = "Cells",

issn = "2073-4409",

publisher = "MDPI AG",

number = "1",

}

TY - JOUR

T1 - The PIKfyve Inhibitor Apilimod

T2 - A Double-Edged Sword against COVID-19

AU - Baranov, Maksim V.

AU - Bianchi, Frans

AU - van den Bogaart, Geert

PY - 2021/1

Y1 - 2021/1

N2 - The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidence from both in vitro studies and the clinic that apilimod blocks antiviral immune responses. We therefore warn that the immunosuppression observed in many COVID-19 patients might be aggravated by apilimod.

AB - The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidence from both in vitro studies and the clinic that apilimod blocks antiviral immune responses. We therefore warn that the immunosuppression observed in many COVID-19 patients might be aggravated by apilimod.

KW - SARS-CoV-2

KW - COVID-19

KW - apilimod

KW - LAM-002A

KW - STA-5326

KW - PIKfyve

U2 - 10.3390/cells10010030

DO - 10.3390/cells10010030

M3 - Article

SN - 2073-4409

VL - 10

JO - Cells

JF - Cells

IS - 1

M1 - 30

ER -

The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19

Samenvatting

Toegang tot document

Handle.net

Vingerafdruk

Citeer dit